PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders
Jun 2, 2022
PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds
May 30, 2022
PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones
May 16, 2022
PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound
May 6, 2022
PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio Development
Apr 29, 2022
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Apr 27, 2022
PsyBio Therapeutics Begins Filing Global Provisional Patent Conversion Applications to Further Strengthen Biosynthetic Patent Portfolio
Apr 25, 2022
KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th
Apr 19, 2022
PsyBio Therapeutics to Participate in Upcoming Investor Conferences in April 2022
Apr 13, 2022
PsyBio Therapeutics Initiates Clinical Trial Site Selection Process
Mar 23, 2022
PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
Mar 15, 2022
PsyBio Therapeutics Announces Proposed Acquisition of Everest Pharma (Pty) Ltd., a Lesotho Company in Southern Africa, as Part of Its Ongoing Impact Investment Strategy
